Artificial intelligence (AI) is revolutionizing precision oncology by analyzing large datasets to guide personalized cancer care. It improves diagnosis, treatment selection, drug development, and risk assessment, leading to better patient outcomes.
In diagnostics, AI rapidly interprets medical images and digital pathology slides, detecting subtle patterns and classifying cancer subtypes with high accuracy. It also predicts disease progression and helps prognosticate outcomes, such as in non-metastatic prostate cancer. For treatment, AI integrates genomics, clinical history, and tumor characteristics to recommend targeted therapies or immunotherapies while optimizing radiation plans to minimize healthy tissue damage.
AI accelerates drug discovery by identifying targets, predicting efficacy, and designing new compounds. It also assesses individual cancer risk, enabling targeted screening and earlier detection. Overall, AI enhances survival, reduces treatment delays, improves quality of life, and supports clinicians with data-driven decisions, making cancer care more precise, efficient, and effective.